Kevin Sharer, CEO of Amgen, assesses the problems he faced, as the main product has been exposed to the regulatory authorities. "Hide
by William W. George Source: Harvard Business School 5 pages. Publication Date: September 10, 2008. Prod. #: 409037-PDF-ENG
Related Case Solutions & Analyses:
Napo Pharmaceuticals
El Farol
Hancock Land Co. and Hancock Lumber Co. (A)
John Smithers at Sigtek
New York City Against AIDS Video
Merck & Co. Inc. (A)
AMB Property Corporation: Navigating Treacherous Waters
ALLIANCE DESIGN CONCEPTS FOREIGN EXCHANGE RISK
Brazos Partners and the Tri-Northern Exit
EVOLUTION
